Pharmaceutical composition, processes to inhibit mast cell degranulation, to treat asthma in a patient, to treat inflammation in a patient, to inhibit the release of cytokines in a patient, to inhibit the release of histamines in a patient, to inhibit the release of leukotrienes in a patient, to reduce the adhesion, migration and aggregation of lymphocytes, eosinophils and neutrophils to a site of inflammation in a patient, to reduce the production of ige antibodies at the site of inflammation in a patient, to inhibit increased vascular permeability in inflammation site in a patient, and to treat chronic inflammation in a patient.

摘要

"PHARMACEUTICAL COMPOSITION, PROCESSES TO INHIBIT MASTOCYTE DEGRANULATION, TO TREAT ASTHMA IN A PATIENT, TO TREAT INFLAMMATION IN A PATIENT, TO INHIBIT THE RELEASE OF CYTOKINES IN A PATIENT, TO INHIBIT LIBERATION RELEASE, TO RELEASE A RELEASE OF LIBERATION IN A PATIENT OF LEUCOTRIENES IN A PATIENT, TO REDUCE ADHESION, MIGRATION AND AGGREGATION OF LYMPHOCYTES, EOSINOPHILES AND NEUTROPHILES TO A PLACE OF INFLAMMATION IN A PATIENT, TO REDUCE THE PRODUCTION OF ANTIBODIES IN ITS EMITTING, IN A PLACE OF INFLAMMATION IN A PATIENT, TO INHIBIT THE INCREASED VASCULAR PERMEABILITY IN A PLACE OF INFLAMMATION IN A PATIENT, AND, TO TREAT CHRONIC INFLAMMATION IN A PATIENT "A pharmaceutical composition is described as a mixture of a pharmaceutical vehicle and a peptide having the formula : f-Met-Leu-X. X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe, and Phe-Tyr. Processes for inhibiting mast cell degranulation and for treating inflammation in a patient are also described, for example where the inflammation is the result of a disease selected from the group consisting of asthma, rheumatoid arthritis, and anaphylaxis. In addition, processes are described to inhibit the release of cytokines in a patient, to inhibit the release of histamines in a patient, to inhibit the release of leukotrienes in a patient, to reduce the adhesion, migration and aggregation of lymphocytes, eosinophils, and neutrophils to an inflammation site in a patient, to reduce the production of IgE antibodies at the inflammation site in a patient, and to inhibit increased vascular permeability at the inflammation site in a patient. The processes use the pharmaceutical composition described.